MSD’s Phase IIb study of tulisokibart achieves primary endpoint
The trial demonstrated that both high- and medium-dose regimens achieved superiority over placebo at week 16.
News
Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies
Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial
Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Clywedog reports final Phase Ib trial results for balomenib
Roivant reports top-line data from IMVT-1402 CLE trial
Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen
Alkermes reports positive top-line Phase Ib trial data for ALKS 7290
